Introduction
As acute myocardial infarction (AMI) remains a major cause for death worldwide, new therapeutic strategies to prevent the cell death occurring during AMI are highly desired. In addition to the cardiac damage that develops due to ischemia, the re-opening of the occluded coronary artery, the so-called reperfusion, has been identified as a major trigger of cardiac cell death. 1 We and others have shown that the pharmacological activation of the nitric oxide-sensitive guanylyl cyclase (NO-GC) and an inhibition of cGMP-degrading cardiac PDE may confer cardioprotection via the cyclic guanosine-3 0 , 5 0 -monophosphate (cGMP)/cGMP-dependent protein kinase I (cGKI) pathway. [2] [3] [4] [5] [6] Additionally, ischemic postconditioning (iPost), which refers to a series of short repetitive episodes of vessel occlusion following immediate reperfusion directly after the prolonged ischemia, has proven to be a successful strategy to reduce infarct size in several animal studies. 7 It remains largely unclear, however, if infarct-limiting iPost and cGMP-elevating agents acting via NO-GC utilize similar signalling mechanisms and cell types during cardiac ischemia and reperfusion (I/R). NO-GC is one of the two known guanylyl cyclases responsible for generating cardiac cGMP. Two isoforms of the NO-GC holoenzyme exist that require assembly of either the a 1 or a 2 subunit with a common b 1 subunit. Accordingly, global deletion of the b 1 subunit leads to complete loss of NO-GC catalytic activity as observed in NO-GC-deficient mice (NO-GC KO). 8 This global NO-GC KO model develops a severe and rapidly progressing phenotype characterized by a massive increase in blood pressure (BP) and intestinal dysmotility with the latter being the major cause for their premature death. 8 Reportedly, the a 1 b 1 heterodimer represents the predominant NO-GC isoform in the cardiovascular system 9, 10 ; however, ablation of a 1 in mice, in contrast to b 1 deficiency, did not alter gastrointestinal transit time or life expectancy and results in a rather moderate increase in BP. 11 These findings suggest that low abundance of the a 2 b 1 holoenzyme in the cardiovascular system is sufficient in order to substitute for most biological functions of the NO-GC/cGMP pathway in vivo. Langendorff-perfused isolated hearts derived from an alternative NO-GC mouse model lacking functional a 1 subunits and thereby an NO-sensitive a 1 b 1 further supported the notion that ischemic preconditioning (iPre) requires only a minimal NO-GC activity to oppose the cardiac injury induced by I/R. 12 However, this ex vivo report did not discriminate between the NO-GC function in CMs or other cardiac cells and it also raised questions about the compensatory upregulation of the a 2 b 1 holoenzyme in a 1 -mutant NO-GC hearts. 12, 13 It is difficult to validate the impact of the endogenous NO-GC/cGMP pathway on the cardiac I/R injury in the currently available mouse models, which are either globally deficient for the NO receptor a isoforms, completely lack catalytic NO-GC activity, or carry a NO-insensitive NO-GC b 1 isoform. 8, [11] [12] [13] [14] Therefore, we investigated gene-targeted mice lacking functional NO-GC exclusively in the CM (CM NO-GC KO). CM NO-GC KO mice were assessed in comparison to CM NO-GC littermate controls (CM NO-GC CTR) using a well-established protocol of experimental AMI in vivo. 2, 15, 16 By applying pharmacological modulators of the NO-GC/cGMP pathway or mechanical iPost procedures, we also elucidated whether these infarct-limiting interventions rely on NO-GC in the CM itself.
Methods

Experimental mice
All animal experiments were performed with permission of the local authorities and conducted in accordance with the German legislation and the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. ) were generated by crossing transgenic mice carrying a floxed exon 10 of the b 1 subunit 8 with an inducible CM-specific Cre mouse line (aMHC-CreERT2 Tg/þ ). 17 For the CM-specific inactivation of the NO-GC holoenzyme tamoxifen (1 mg/day i.p. dissolved in Miglyol 812) was injected on five consecutive days. Fifty days after the injection mice were used for subsequent experiments. 18 
Acute model of myocardial infarction
For studying I/R injury an open-chest, in situ model was used in sodium pentobarbital (70 mg/kg i.p.) anesthetized male and female mice as previously described. 2, 19, 20 If needed, additional anesthesia was administered as adequate anesthetic depth was controlled via corneal and withdraw reflexes throughout the surgery. Occlusion of the left coronary artery was maintained for 30 min to induce myocardial ischemia. Subsequently, 2 h of reperfusion were allowed (see Supplementary material online, Figure S1 , ). After the I/R procedure, mice were killed by cervical dislocation and hearts were removed and processed for further analysis. Details regarding the different treatment protocols are summarized in Supplementary material online, Figure S1 . An expanded Methods section can be found in the Supplementary material online.
Results
As the NO-GC/cGMP pathway is an important determinant of BP, we first measured systolic and diastolic BP ( Figure 1A þ B) in CM-specific NO-GC knockout (CM NO-GC KO) and litter-matched control mice (CM NO-GC CTR). Consistent with the concurrent elevation of both systolic and diastolic values, mean arterial pressure (MAP) was higher in CM NO-GC KO (116 ± 2 mmHg, n = 6) as compared with control siblings (107 ± 2 mmHg, n = 4) ( Figure 1C ), whereas no alterations in heart rate, pulse pressure or activity could be observed between both genotypes ( Figure 1D-F) .
To assess whether the CM-specific deletion of NO-GC affected infarct size, we subjected CM NO-GC CTR and KO mice to the acute model of MI. Risk zones (in % of the total heart area) were determined as a marker for the reproducibility of the surgery and did not differ between genotypes and setups ( Figure 2A , n = 8; Figure 2B ). Importantly, neither the drop in BP ( Figure 2C ) nor heart rate (data not shown) during pentobarbital sodium anesthesia was affected by the deletion of NO-GC in the CM. In contrast, cardioprotection induced by an established iPost protocol efficiently reduced infarct size by 50.7 ± 5.3% in control mice (11.85 ± 1.28%, n = 5; Figure 2B and D), whereas lack of NO-GC in CM completely abolished the favourable effects of iPost (24.04 ± 1.60%, n = 8; Figure 2B and D). Corroborating the essential role of CM NO-GC for the protection afforded by iPost, the pharmacological NO-GC activator cinaciguat (CIN) reduced the amount of cardiac damage in control mice by 53.6 ± 6.0% (11.15 ± 1.43%, n = 5; Figure 2E and F) but not in CM NO-GC KO mice (24.41 ± 1.39%, n = 8). Depletion of the endogenous NO production with the NO synthase inhibitor N x -nitro-L-arginine methyl ester hydrochloride (L-NAME), however, did not affect the amount of infarction that developed during I/R in CM NO-GC KO (22.30 ± 1.88%, n = 8) or in CTR mice (21.53 ± 1.39%, n = 5; Figure 2G ), suggesting that the NOstimulated activity of the CM NO-GC is not involved in the basal I/R response. Infarct sizes were not L-NAME-sensitive even though we observed an elevation in BP which was accompanied by a reduction in heart rate in L-NAME-treated CM NO-GC-deficient and proficient mice (see Supplementary material online, Figure S4 ).
Next, we analyzed the link between cardioprotective CM NO-GC and agents that elevate cGMP, i.e. the PDE5 inhibitors. Previously, animal studies have identified that the PDE5 inhibitors sildenafil (SIL) and tadalafil (TAD) counteract cardiac damage induced by I/R. 2, 4, 6, 21 Administration of SIL 5 min before reperfusion and TAD applied 60 min prior to ischemia protected CM NO-GC CTR (9.50 ± 0.77% for
I/R þ SIL; 9.89 ± 0.68% for I/R þ TAD; n = 5 each, Figure 3A þ B, left). Compared to the absence of PDE5 inhibitors, SIL and TAD reduced the infarct area by 60.4 ± 3.2% and 58.8 ± 2.8%, respectively ( Figure 3C ). In contrast, CM NO-GC KO hearts did not respond to PDE5 inhibitors with a reduction in infarct size (23.26 ± 0.52% for I/R þ SIL; 20.76 ± 0.83% for I/R þ TAD, n = 8 each). Importantly, control injections of the solvent (ctr 1 , ctr 2 ) did not influence the amount of myocardial damage per se ( Figure 3A þ B, right) . The apparent failure of PDE inhibitors to protect against I/R injury in CM NO-GC-deficient mice was not due to an unexpected effect on BP because we observed a similar decrease in MAP after TAD in both genotypes (-14.6 ± 3.8% for CM NO-GC þ/fl , n = 4; -13.9 ± 3.1% for CM NO-GC -/fl , n = 6; Figure 3D) . Accordingly, the TAD treatment only marginally affected heart rate (data not shown). Basal I/R parameters of the CM NO-GC KO and CTR mice, which were subjected to I/R, are summarized within see Supplementary material online, Table S1 .
Thus, the NO-GC/cGMP pathway in CMs is essential for the cardioprotection through cGMP-elevating agents and iPost during AMI. Mitochondrial potassium channels, by limiting generation of excessive reactive oxygen species (ROS) production and Ca 2þ uptake, have gained increasing attention as key elements of numerous cardioprotective pathways. 22 We and others have previously identified mitochondrial largeconductance and Ca 2þ -dependent potassium channels (BK) as important effector molecules downstream of the NO-GC/cGMP signalling pathway in CMs at I/R. 16 ,23 Therefore, we tested whether mito-and cytoprotective treatments related to the activation of mitochondrial BK channels remained intact in the CM-specific NO-GC-deficient mouse model. 24 By applying the BK opener NS11021 at the end of the ischemic insult, myocardial damage was decreased to a similar extent in both genotypes (11.14 ± 2.08% for CM NO-GC þ/fl , n = 5; 13.02 ± 1.39% for CM NO-GC -/fl , n = 8; Figure 4A and B) suggesting that beneficial effects mediated by BK channels at the inner mitochondrial membrane of CMs 16 remain present even in the absence of CM NO-GC.
Besides BK, mitochondrial ATP-sensitive potassium (K ATP ) channel have been implicated in cardioprotection by iPre and iPost and by pharmacological agents that stimulate cGMP signalling. 25 
Discussion
Pharmacological agents that stimulate the NO-GC/cGMP signalling pathway represent a promising strategy in order to prevent cell death caused ; n = 5) after 30 min ischemia followed by 120 min reperfusion (I/R). iPost evoked a significant reduction in infarct size in CM NO-CTR (n = 5) but not in CM-specific NO-GC-deficient mice (n = 8). Two representative Evan's Blue and TTC stained heart slices per genotype and setup (blue indicates unaffected tissue (i.e. area not at risk); red plus white: risk zone; white: infarcted tissue) are shown in the lower part of the panel. .001 to respective I/R group. Significance levels of (A) and (B) were also tested using one-way ANOVA with similar results.
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by MI as well as the reperfusion injury occurring during the clinical reopening of the occluded vessel. [2] [3] [4] 15, 21, 31 Components of this pathway are ubiquitously present across different cell types in the heart and cardiovascular system and the number of molecules that mediate these beneficial effects is increasing over the last years. 28, 32, 33 Consequently, neither the type of cells nor their precise involvement in the cardioprotective mechanisms triggered by different cGMP-elevating agents are not yet well-known. In this regard, we recently identified mitochondrial BK channels in CMs as a target for the infarct-limiting effect of NO-GC stimulators/activators. Mechanistically, this finding supported the notion that NO-GC activity in the CM itself can modulate the I/R injury in vivo. 16 The herein generated CM-specific NO-GC null mutants allowed us to investigate the impact of the CM NO-GC and cGMP for cardiac I/R injury under basal and conditioning circumstances. The amount of infarction in CM NO-GC-deficient hearts was not augmented by exposure to 30 min of ischemia followed by 120 min reperfusion ( Figure 2B) . This is in line with previous data from mice lacking cGKI exclusively in CM. 2 Ex vivo data from isolated hearts studying either a NO-insensitive NO-GC a 1 mutant 12 or a pharmacologically inhibited NO-GC 34 revealed no significant effects on the infarct size in response to the I/R stimulus. Accordingly, L-NAME did not exaggerate the cardiac I/R damage in the open-chest model despite a substantial increase in BP observed in both genotypes (see Supplementary material online, Figure S4 ). Because absence of CM-specific NO-GC did not render the hearts more vulnerable during I/R alone ( Figure 2B, left) or following the short-term treatment with L-NAME ( Figure 2G) , we conclude that a low or baseline activity of the NO-GC/cGMP pathway in the CM does not modulate the cardiac damage occurring after I/R. In contrast, CM NO-GC activity is indispensable for cardioprotection elicited by iPost and pharmacological cGMP-elevation since CM NO-GC KO mice were resistant to their effects ( Figure 2B þ D) . These findings appear to be in conflict with our previous data implicating that the cardioprotective signalling elicited by iPost may be independent of CM cGKI. 2 In this earlier study, iPost protected mice lacking cGKI specifically in CMs even in the presence of the NO-GC inhibitor ODQ. However, the cardiac I/R phenotypes of the CM-specific cGKI and herein studied CM-specific NO-GC KO mice were assessed by utilizing mouse models that carry different Cre recombinase transgenes, i.e. the MLC2a-Cre strain and a tamoxifen-induced aMHC-CreERT2 line, respectively. The expression of the MLC2a-driven Cre recombinase is starting early in embryogenesis, i.e. approximately at E8. Hence, lack of CM cGKI during embryonic and fetal growth and development may allow for unexpected genetic compensations and thus an adequate response of the cGKI null hearts to the iPost stimuli. In contrast, CM NO-GC gene activity in the herein used aMHC-CreERT2 positive mice was blocked using tamoxifen only in adult mice. This acute targeting of NO-GC very efficiently abolished the damage limiting effects of our iPost protocol. So far, we did not directly compare the specificity of expression and efficiency of recombination caused by both Cre transgenes. It therefore seems also possible that a residual pool of inadequately targeted cGKI-positive CMs in the MLC2a-Cre transgenic mouse model was sufficient in order to mediate the effects of iPost in the I/R-exposed heart. In contrast, the aMHC-CreERT2-induced ablation of the NO-GC gene revealed an essential role of the CM NO-GC pathway for the cardioprotection elicited by iPost. Sips et al. 12 observed that iPre maneuvers efficiently protected Langendorff-perfused hearts derived from NO-GC a 1 -deficient mice ex-vivo. As iPre and iPost may elicit their cardioprotection by similar as well as divergent pathways an explanation for these conflicting findings on the role of NO-GC in I/R remains a challenge. Moreover, in a 1 -deficient mice with blunted NO-GC responsiveness towards NO, the a 2 -subunit may be a functional substitute for the loss of the other isoform, whereas the ablation of the b 1 -subunit should result in a complete depletion of NO-GC in CMs. 8, 35 Compounds that imitate the beneficial effects of ischemic conditioning have been extensively studied with regard to the NO-GC/cGMP pathway (i.e. hydrogen sulfide 32, 33 ). Modulation of NO-GC either by specific stimulators 15, 16 or activators 2, 3, 36 prevented cardiac damage during AMI.
By studying the CM NO-GC-deficient mouse model, we demonstrated that the protection afforded by the activator CIN requires NO-GC activity in the CMs further suggesting CM NO-GC/cGMP as a main target for pharmacological approaches that are thought to have a cardioprotective effect similar to that of mechanical conditioning. In addition to iPost and NO-GC activation, the I/R-induced infarct size was sensitive to PDE5 inhibition by SIL ( Figure 3A þ C) , which is in agreement with previous reports. [4] [5] [6] Remarkably, absence of CM NO-GC prevented the protection seen with SIL. Because it is difficult to rule out that SIL after its intra-atrial injection inhibited other SIL-sensitive cGMP-PDEs in the heart, we used TAD as a highly specific PDE5 inhibitor. 36 Again, the protective effects elicited by TAD were absent in CM-specific NO-GC-deficient hearts, confirming that PDE5 inhibitors act distal of CM NO-GC in cardioprotection via cGMP ( Figure 3B þ C) . However, an ongoing debate exists regarding the distribution of PDE5 in the murine heart and its presence in the CM itself. 6, 36, 37 Considering the systemic administration of PDE5 inhibitors, these agents may also have impact on cardiac fibroblasts, smooth muscle cells or endothelial cells and on non-cardiac tissues. In this view, it is also conceivable that modulation of PDE5 activity during I/R occurs upstream of CM NO-GC. Mitochondrial dysfunction is a key pathologic event in I/R injury and it is well accepted that mitochondria are targeted by different pathways including signals through cGMP to produce cardioprotection in CMs. 16, 38 In order to test whether mitochondrial-based cardioprotection can be elicited when NO-GC function is impaired we directly stimulated BK that represents one class of cGMP-regulated potassium channels present at the inner mitochondrial membrane. 16, 22 Opening of mitochondrial potassium channels during I/R has been seen to prevent harmful events such as the massive Ca 2þ overload of the mitochondrion and bursts of ROS production. 24, [39] [40] [41] [42] Our data imply that favourable effects associated with the administration of the BK opener NS11021 on infarct size do not require functional CM NO-GC ( Figure 4A þ B) as mitochondria-based cardioprotection remains intact in CM NO-GCdeficient hearts. This notion is further supported by our finding that the infarct limiting effects of CIN, which was used herein as a pharmacological pre-conditioning agent were sensitive to mK ATP inhibition with 5-HD (see Supplementary material online, Figure S5A þ B) . Apparently, the cardioprotective signalling via CM NO-GC is linked to different types of mitochondrial potassium channels, i.e. to the opening of mK ATP and mitochondrial BK channels. 16 Opening of mitochondrial K ATP channels has been widely shown to limit the necrotic cell death that occurs during I/R [43] [44] [45] ; although the specificity of 5-HD is still a matter of ongoing debate, additional effects of this agent on mitochondrial function or other potassium channels, i.e. the mitochondrial BK which protects CMs from I/R injury in vivo, cannot be excluded. [46] [47] [48] A schematic overview summarizing the above-mentioned NO-GC/cGMP-dependent signalling events targeting myocyte mitochondria and different types of mitochondrial potassium channels during I/R are shown in Supplementary material online, Figure S6 . The relevance of the NO-GC/cGMP pathway in BP regulation has already been shown by a number of studies using either pharmacological or genetic approaches to modulate the activity of NO-GC. 11, 13, 18 In line with these findings, our present data suggest that a CM-specific NO-GC pathway contributes, at least partly, to the physiological BP regulation in vivo (Figure 1) . Although the molecular details underlying the observed Cardiomyocyte NO-GC in ischemia/reperfusion injury hypertensive phenotype resulting from loss of CM NO-GC need to be determined, previous analysis of Langendorff-perfused hearts derived from a global NO-GCa 1 mouse knockout model imply that a depletion of the major cardiac NO-GC isoform, which is NO-GCa 1 , has a positive inotropic effect. 12 To this end, we conclude that heart muscle contractility-a major determinant of cardiac output and BP-is controlled by CM NO-GC. In summary, our findings imply a crucial role for a CM-specific NO-GC pathway in cardioprotection. iPost, pharmacological PDE5 inhibition and agents that directly target NO-GC act via an activation of this enzyme in CMs in order to oppose the I/R-induced cardiac damage.
